Synopsis
Synopsis
0
VMF
0
Canada
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
2. (2-(4-((r)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic Acid
3. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
4. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
5. Cetirizine (r)-form Dihydrochloride
6. Levocetirizine
7. Levocetirizine Hydrochloride
8. Levocetrizine
9. Ucb-28556
10. Xusal
11. Xyzal
1. 130018-87-0
2. Xyzal
3. Xusal
4. (r)-cetirizine Dihydrochloride
5. Levocetirizine Hcl
6. Levocetirizine Dihydrochloride [usan]
7. Cetirizine (r)-form Dihydrochloride
8. Ucb-28556
9. Sod6a38aga
10. Ucb 28556
11. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
12. (r)-2-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
13. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
14. Nsc-758898
15. Levocetirizine Hydrochloride (jan)
16. (-)-cetirizine Dihydrochloride
17. 2-[2-[4-[(r)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid;dihydrochloride
18. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic Acid Dihydrochloride
19. Levocetirizine (dihydrochloride)
20. Levocetirizine Hydrochloride [jan]
21. Levocetirizine 2hcl
22. Unii-sod6a38aga
23. Levocetirizine Dihcl
24. Mfcd07366507
25. Xyzal Allergy 24hr
26. Xyzal (tn)
27. Levocetirizinedihydrochloride
28. Schembl144375
29. Chembl1201190
30. Levocetirizine Hydrochloride,(s)
31. Dtxsid30926567
32. Bcp21544
33. Ac-549
34. Levocetirizine Dihydrochloride (usp)
35. S4849
36. Akos015994681
37. Ccg-269359
38. Cs-w011557
39. Hy-w010841
40. Ks-1177
41. Nsc 758898
42. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid 2hcl
43. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride
44. Levocetirizine Hydrochloride [mart.]
45. L0264
46. Levocetirizine Dihydrochloride [vandf]
47. Levocetirizine(r)-cetirizine (hydrochloride)
48. D08118
49. Levocetirizine Dihydrochloride [usp-rs]
50. Levocetirizine Dihydrochloride [who-dd]
51. Levocetirizine Dihydrochloride, >=98% (hplc)
52. Cetirizine (r)-form Dihydrochloride [mi]
53. 018l870
54. Levocetirizine Dihydrochloride [orange Book]
55. Levocetirizine Dihydrochloride [usp Monograph]
56. Q27289313
57. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid Dihydrochloride
Molecular Weight | 461.8 g/mol |
---|---|
Molecular Formula | C21H27Cl3N2O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 8 |
Exact Mass | 460.108726 g/mol |
Monoisotopic Mass | 460.108726 g/mol |
Topological Polar Surface Area | 53 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 443 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 4 | |
---|---|
Drug Name | Levocetirizine dihydrochloride |
Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
2 of 4 | |
---|---|
Drug Name | Xyzal |
PubMed Health | Levocetirizine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Ucb |
3 of 4 | |
---|---|
Drug Name | Levocetirizine dihydrochloride |
Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
4 of 4 | |
---|---|
Drug Name | Xyzal |
PubMed Health | Levocetirizine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Ucb |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34731
Submission : 2020-05-12
Status : Active
Type : II
Registration Number : 302MF10110
Registrant's Address : Flat No. 302, Bhanu Enclave, Sunder Nagar, Erragadda, Hyderabad - 500038, Telangana, India
Initial Date of Registration : 2020-09-14
Latest Date of Registration : --
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-008
Start Marketing Date : 2020-03-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-08-17
Pay. Date : 2013-08-07
DMF Number : 21417
Submission : 2008-03-11
Status : Active
Type : II
Date of Issue : 2022-07-07
Valid Till : 2025-07-21
Written Confirmation Number : WC-0150
Address of the Firm :
NDC Package Code : 17511-106
Start Marketing Date : 2020-01-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Klasia Co., Ltd.
Registration Date : 2022-06-03
Registration Number : 20110429-40-C-279-18(2)
Manufacturer Name : Cohance Lifesciences Limited
Manufacturer Address : RS No.50/1, Mukteswarapuram Village, Jaggaiahpet Mandal, NTR District-521 457, Andhra Pradesh, India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-03-10
Pay. Date : 2017-02-22
DMF Number : 21005
Submission : 2007-11-02
Status : Active
Type : II
Date of Issue : 2022-06-15
Valid Till : 2025-06-25
Written Confirmation Number : WC-0035A3
Address of the Firm :
NDC Package Code : 55111-045
Start Marketing Date : 2013-10-09
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
(-) -(4-Chlorophenyl) Phenyl] Methyl Amine
CAS Number : CAS-163837-57-8
End Use API : Levocetirizine Dihydrochloride
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
(-)-1-(4-ChloroPhenyl) Phenyl Methyl) Piperazine
CAS Number : CAS-300543-56-0
End Use API : Levocetirizine Dihydrochloride
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
(-)-2-[4-[(4-Chlorophenyl) Phenyl Methyl]- 1-Piper...
CAS Number : CAS-705289-61-8
End Use API : Levocetirizine Dihydrochloride
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
N, N Dichloroethyl-4-Methoxy Benzene Sulphonamide
CAS Number : CAS-86357-59-7
End Use API : Levocetirizine Dihydrochloride
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
(R )-((4-Chlorophenyl)) Phenylmethyl) Piperazine
CAS Number : 300543-56-0
End Use API : Levocetirizine Dihydrochloride
About The Company : NAM Group of Industries is a prominent manufacturer and exporter of pharmaceutical API’s for both human and veterinary use, along with pharmaceutical intermed...
(-)-1-[4-(CHLOROPHENYL)PHENYL METHYL ] PIPERAZINE
CAS Number : CAS-130018-88-1
End Use API : Levocetirizine Dihydrochloride
About The Company : OM Pharmaceutical Industries is one of the established pharmaceutical company in India, which is engaged in manufacturing of Active Pharmaceutical Ingredients (...
(R)-1-((4- Chlorophenyl)(phenyl)methyl) piperazine
CAS Number : 300543-56-0
End Use API : Levocetirizine Dihydrochloride
About The Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediate...
N,N-Bis(2-chloroethyl)-4- methylbenzenesulfonamide
CAS Number : 42137-88-2
End Use API : Levocetirizine Dihydrochloride
About The Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediate...
(R)-1-[(4-Chlorophenyl)phenylmethyl]piperazine
CAS Number : -300543-56-0
End Use API : Levocetirizine Dihydrochloride
About The Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediate...
(R)-1 - [(4-Chloro Phenyl) Phenyl Methyl ] Piperaz...
CAS Number : 300543-56-0
End Use API : Levocetirizine Dihydrochloride
About The Company : Synthetic Molecules Pvt. Ltd (SMPL) is glad to introduce ourselves as established pharmaceutical manufacture & reputed trading house catering the ranges of Inte...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Levocetirizine Dihydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levocetirizine Dihydrochloride, including repackagers and relabelers. The FDA regulates Levocetirizine Dihydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levocetirizine Dihydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Levocetirizine Dihydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Levocetirizine Dihydrochloride supplier is an individual or a company that provides Levocetirizine Dihydrochloride active pharmaceutical ingredient (API) or Levocetirizine Dihydrochloride finished formulations upon request. The Levocetirizine Dihydrochloride suppliers may include Levocetirizine Dihydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Levocetirizine Dihydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Levocetirizine Dihydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Levocetirizine Dihydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Levocetirizine Dihydrochloride DMFs exist exist since differing nations have different regulations, such as Levocetirizine Dihydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Levocetirizine Dihydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Levocetirizine Dihydrochloride USDMF includes data on Levocetirizine Dihydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Levocetirizine Dihydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Levocetirizine Dihydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Levocetirizine Dihydrochloride Drug Master File in Japan (Levocetirizine Dihydrochloride JDMF) empowers Levocetirizine Dihydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Levocetirizine Dihydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Levocetirizine Dihydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Levocetirizine Dihydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Levocetirizine Dihydrochloride Drug Master File in Korea (Levocetirizine Dihydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Levocetirizine Dihydrochloride. The MFDS reviews the Levocetirizine Dihydrochloride KDMF as part of the drug registration process and uses the information provided in the Levocetirizine Dihydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Levocetirizine Dihydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Levocetirizine Dihydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Levocetirizine Dihydrochloride suppliers with KDMF on PharmaCompass.
A Levocetirizine Dihydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Levocetirizine Dihydrochloride Certificate of Suitability (COS). The purpose of a Levocetirizine Dihydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Levocetirizine Dihydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Levocetirizine Dihydrochloride to their clients by showing that a Levocetirizine Dihydrochloride CEP has been issued for it. The manufacturer submits a Levocetirizine Dihydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Levocetirizine Dihydrochloride CEP holder for the record. Additionally, the data presented in the Levocetirizine Dihydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Levocetirizine Dihydrochloride DMF.
A Levocetirizine Dihydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Levocetirizine Dihydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Levocetirizine Dihydrochloride suppliers with CEP (COS) on PharmaCompass.
A Levocetirizine Dihydrochloride written confirmation (Levocetirizine Dihydrochloride WC) is an official document issued by a regulatory agency to a Levocetirizine Dihydrochloride manufacturer, verifying that the manufacturing facility of a Levocetirizine Dihydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Levocetirizine Dihydrochloride APIs or Levocetirizine Dihydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Levocetirizine Dihydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Levocetirizine Dihydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Levocetirizine Dihydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Levocetirizine Dihydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Levocetirizine Dihydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Levocetirizine Dihydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Levocetirizine Dihydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Levocetirizine Dihydrochloride suppliers with NDC on PharmaCompass.
Levocetirizine Dihydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levocetirizine Dihydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levocetirizine Dihydrochloride GMP manufacturer or Levocetirizine Dihydrochloride GMP API supplier for your needs.
A Levocetirizine Dihydrochloride CoA (Certificate of Analysis) is a formal document that attests to Levocetirizine Dihydrochloride's compliance with Levocetirizine Dihydrochloride specifications and serves as a tool for batch-level quality control.
Levocetirizine Dihydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Levocetirizine Dihydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levocetirizine Dihydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Levocetirizine Dihydrochloride EP), Levocetirizine Dihydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levocetirizine Dihydrochloride USP).
LOOKING FOR A SUPPLIER?